Satellos changes BASECAMP Phase 2 primary endpoint to MRI-measured muscle fat fraction after FDA feedback
What's the deal? On 6 November 2026, Satellos BioscienceDealroom has a profile for this one. Try Dealroom → announced that, following feedback from the US Food and Drug Administration (FDA), it has changed the primary efficacy endpoint of its BASECAMP Phase 2 trial to the change in muscle fat fraction of the vastus lateralis (a thigh muscle) measured by MRI. The endpoint replaces dynamometry (a machine-based measure of muscle strength). BASECAMP is a global, randomised, double-blind, placebo-controlled study of forazapadin — an investigational oral medicine designed to boost the body's natural ability to repair and regenerate muscle — in 53 ambulatory boys aged 7–9 with Duchenne muscular dystrophy (DMD), a severe inherited condition in which muscles progressively weaken.
Why it matters: DMD has no cure, and measuring treatment effect in young boys is difficult. MRI-measured fat fraction tracks how much muscle has been replaced by fat as the disease progresses. Satellos believes it may serve as a surrogate endpoint reasonably likely to predict clinical benefit — one that, together with clinical endpoints, could support a potential accelerated approval pathway for forazapadin. The company points to its earlier open-label Phase 2 TRAILHEAD study in adults with DMD, which showed a mean 3.7 percentage-point reduction in MRI-measured fat fraction (from 49.7% to 46.0% at day 140). A protocol amendment to implement the new endpoint has been submitted, and topline 12-week placebo-controlled BASECAMP data are expected in Q1 2027.
Read more: GlobeNewswire, 6 November 2026
